JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, is opening a lab in the Discovery Oasis biotechnology space in Phoenix, Arizona.
An expansive 120-acre development, Discovery Oasis is envisioned as a biotechnology corridor of collaboration to advance groundbreaking solutions to humanity's most complex medical challenges. With around 1,100 square feet of space housing some of its most advanced equipment, JelloX will leverage its new lab for applying cutting-edge technologies like 3D imaging and AI to cancer pathology.
"Medical problems like cancer require many parties working together to create better treatments and patient care," commented Dr. Yen-Yin Lin, CEO of JelloX. "With all the promise 3D pathology offers, we are thrilled to establish a research base in the US, particularly one where we can work hand-in-hand with other pioneering companies to fight cancer while contributing to the country's leadership in biotech innovation."
As the company's research has consistently shown, the higher sensitivity of 3D methods has real implications for improving diagnosis and treatment in oncology. Traditional methods of tissue sampling offer limited information on a tumor. Methods using 3D pathology can not only identify cases previously classified as "false negatives" but also enable early cancer detection. This allows for earlier treatment initiation and greater precision.
JelloX's recent research collaborations with major healthcare institutions in Japan and Taiwan have consistently shown the value of 3D pathology across demographics and in a variety of cancers, including colorectal cancer, esophageal cancer, and HER2 detection in breast cancer.
